EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies

Salvatore Corrao iD, Marta Moschetti iD, Salvatore Scibetta, Luigi Calvo, Annarita Giardina, Ignazio Cangemi iD, Carmela Zizzo, Paolo Colomba iD, Giovanni Duro

International Journal of Molecular Sciences · 17.08.2025 · 26 (16) · 7931

DOI: 10.3390/ijms26167931 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.08.2025. Verfasst von Salvatore Corrao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 …. Hauptthemen laut MEDLINE: Ubiquitin-Activating Enzymes, Genetic Diseases, X-Linked, Erythema Nodosum. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS syndrome (Vacuoles, E1-enzyme, X-linked, Autoinflammation, and Somatic) is a recently identified late-onset autoinflammatory disorder characterized by a unique interplay between hematological and inflammatory manifestations. It results from somatic mutations in the UBA1 gene, located on the short arm of the X chromosome. Initially, females were considered mere carriers, with the syndrome primarily affecting males over 50. However, recent evidence indicates that heterozygous females can exhibit symptoms as severe as those seen in hemizygous males. The disease manifests as systemic inflammation, macrocytic anemia, thrombocytopenia, chondritis, neutrophilic dermatoses, and steroid-dependent inflammatory symptoms. Due to its overlap with autoimmune and hematologic disorders such as relapsing polychondritis, Still’s disease, and myelodysplastic syndromes, misdiagnosis is common. At the molecular level, VEXAS syndrome is driven by impaired ubiquitination pathways, resulting in dysregulated immune responses and clonal hematopoiesis. A key diagnostic marker is the presence of cytoplasmic vacuoles in myeloid and erythroid precursors, though definitive diagnosis requires genetic testing for UBA1 mutations. Traditional immunosuppressants and TNF inhibitors are generally ineffective, while JAK inhibitors and IL-6 blockade provide partial symptom control. Azacitidine and decitabine have shown promise in reducing disease burden, but hematopoietic stem cell transplantation (HSCT) remains the only curative treatment, albeit with significant risks. This review provides a comprehensive analysis of VEXAS syndrome, examining its clinical features, differential diagnoses, diagnostic challenges, and treatment approaches, including both pharmacological and non-pharmacological strategies. By enhancing clinical awareness and optimizing therapeutic interventions, this article aims to bridge emerging genetic insights with practical patient management, ultimately improving outcomes for those affected by this complex and often life-threatening disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Activating EnzymesGenetic Diseases, X-LinkedErythema NodosumHumansFemaleMaleMutationMyelodysplastic SyndromesSkin Diseases, Genetic

Stichwörter der Autor:innen

VEXAS syndromeX-linked pathologyclinical featureshematological and inflammatory manifestationslyonization affectstherapeutic approaches

Substanzen

Ubiquitin-Activating EnzymesUBA1 protein, human

Autor:innen und Institutionen

  • Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy.
  • Department of Internal Medicine, National Relevance and High Specialization Hospital Trust, ARNAS Civico, Di Cristina, Benfratelli, 90127 Palermo, Italy.
  • Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy.

ORCID-Profile: Salvatore Corrao, Marta Moschetti, Ignazio Cangemi, Paolo Colomba

Zitieren

APA

Corrao, S., Moschetti, M., Scibetta, S., Calvo, L., Giardina, A., Cangemi, I., Zizzo, C., Colomba, P., & Duro, G. (2025). VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies. International Journal of Molecular Sciences, 26(16), 7931. https://doi.org/10.3390/ijms26167931

Vancouver

Corrao S, Moschetti M, Scibetta S, Calvo L, Giardina A, Cangemi I, et al. VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies. International Journal of Molecular Sciences. 2025;26(16):7931. doi:10.3390/ijms26167931

BibTeX
@article{Corrao2025,
  author = {Corrao, Salvatore and Moschetti, Marta and Scibetta, Salvatore and Calvo, Luigi and Giardina, Annarita and Cangemi, Ignazio and Zizzo, Carmela and Colomba, Paolo and Duro, Giovanni},
  title = {VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {16},
  pages = {7931},
  doi = {10.3390/ijms26167931}
}
Kostenlos starten →